Clinical Trials Directory

Trials / Completed

CompletedNCT02431676

Survivorship Promotion In Reducing IGF-1 Trial

Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
121 (actual)
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus self-directed weight loss on insulin-like growth factor (IGF)-1 and IGF-1 to THE IGFBP-III ratio blood levels after 6 and 12 months of intervention. The coach-directed Behavioral Weight Loss arm is a web-based remote delivery and communication system that promotes healthy behavioral changes. The Metformin arm is a pharmaceutical intervention of oral metformin. This is a secondary prevention study for men and women who have survived solid malignant tumors

Conditions

Interventions

TypeNameDescription
DRUGMetforminParticipants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
BEHAVIORALCoach Directed Behavioral Weight LossBehavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
BEHAVIORALSelf-control weight loss

Timeline

Start date
2015-05-01
Primary completion
2018-12-01
Completion
2018-12-01
First posted
2015-05-01
Last updated
2024-08-28
Results posted
2020-09-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02431676. Inclusion in this directory is not an endorsement.